VEGFA and neoplasm: One small study including 7 human participants [40] trialled a molecular fluorescent agent linked to a tumour target (bevacizumab conjugated to the near-infrared fluorescent dye IRDye 800CW that targets tumour VEGF-A) with reported sensitivity and specificity of 100% and 54%, respectively.